Assessing response to treatment in patients with ANCA-associated vasculitis
How should we assess response to treatment in patients with ANCA-associated vasculitis?
How should we assess response to treatment in patients with ANCA-associated vasculitis?
Can clinicians use the Chapel Hill Consensus Conference definitions, European Medicines Agency (EMA) algorithm, or American College of Rheumatology (ACR) classification criteria in the diagnostic workup of patients with vasculitis?
Diagnosis of ANCA-associated vasculitis seems to be much easier with ANCA testing being widely available. Can we confirm or exclude ANCA-associated vasculitis based on the ANCA test result?